Summary & Overview
CPT 90750: Adjuvanted Varicella Zoster Vaccine, Intramuscular Injection
CPT code 90750 represents intramuscular administration of an adjuvanted varicella zoster vaccine, a preventive immunization to reduce the risk of shingles and related complications. Nationally, vaccine administration codes like 90750 are important for capturing preventive services, ensuring appropriate payment for vaccine delivery, and monitoring immunization uptake among eligible populations.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical context for adjuvanted varicella zoster vaccination, typical settings where the service is delivered, and the billing considerations relevant to payers nationwide. The publication outlines benchmarks for utilization and reimbursement trends where available, summarizes recent policy updates affecting vaccine administration billing, and highlights documentation and coding points that influence claim acceptance.
This resource is intended for billing professionals, practice managers, and policy analysts seeking a concise reference on how CPT code 90750 is used in clinical practice and across major payers, along with the operational and policy factors that commonly affect vaccine administration claims.
Billing Code Overview
CPT code 90750 describes the injection of an adjuvanted vaccine administered intramuscularly to protect against varicella zoster infection. The service involves a licensed provider delivering an intramuscular vaccination using an adjuvanted formulation intended to enhance immune response to varicella zoster.
Service Type: Vaccine administration (intramuscular), adjuvanted varicella zoster vaccine
Typical Site of Service: Outpatient clinic, physician office, or other outpatient vaccination setting
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult seeking vaccination against varicella zoster (herpes zoster/shingles) in an outpatient primary care clinic or pharmacy clinic. The patient presents for routine prevention or following clinician recommendation due to age (commonly ≥50 years) or immunocompetent status. The clinical workflow includes patient check-in, review of immunization history and contraindications (e.g., allergy to vaccine components, pregnancy status, immunosuppression), informed consent and counseling about benefits and potential side effects, preparation of the adjuvanted zoster vaccine, intramuscular injection (typically into the deltoid muscle), documentation of vaccine lot number and manufacturer, billing using 90750, and observation for a short period for adverse reactions before discharge.
Common sites of service are outpatient clinic, physician office, and retail pharmacy immunization clinic. The service type is an intramuscular vaccine administration procedure for prevention of varicella zoster infection. Typical patient scenario: a 62-year-old adult with no contraindications receives the adjuvanted zoster vaccine in the deltoid after counseling; vaccine lot and manufacturer are recorded; the patient is observed for 15 minutes and leaves without immediate adverse event.
Coding Specifications
- For the adjuvanted zoster vaccine injection billed as
90750, the following modifiers are most clinically relevant and commonly applied in outpatient immunization settings.
| Modifier | Description | When to Use |
|---|